50
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Computer-aided optimization of carbidopa/levodopa orally disintegrating tablets

, &
Pages 331-340 | Received 21 Oct 2023, Accepted 01 Mar 2024, Published online: 19 Mar 2024

References

  • GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17(11):939–953. doi: 10.1016/S1474-4422(18)30295-3.
  • Pihlstrøm L, Fan CC, Frei O, et al. Genetic stratification of age-dependent Parkinson’s disease risk by polygenic hazard score. Mov Disord. 2022;37(1):62–69. doi: 10.1002/mds.28808.
  • Müller T. Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for parkinson’s disease. Expert Opin Drug Metab Toxicol. 2020;16(5):403–414. doi: 10.1080/17425255.2020.1750596.
  • Trenkwalder C, Kuoppamäki M, Vahteristo M, et al. Increased dose of carbidopa with levodopa and entacapone improves “off” time in a randomized trial. Neurology. 2019;92(13):e1487–e1496. doi: 10.1212/WNL.0000000000007173.
  • Müller T, Möhr J-D. Efficacy of carbidopa-levodopa extended-release capsules (IPX066) in the treatment of Parkinson disease. Expert Opin Pharmacother. 2018;19(18):2063–2071. doi: 10.1080/14656566.2018.1538355.
  • Khadem NR, Nirenberg MJ. Carbidopa/levodopa pharmacy errors in Parkinson’s disease. Mov Disord. 2010;25(16):2867–2871. doi: 10.1002/mds.23311.
  • Suttrup I, Warnecke T. Dysphagia in Parkinson’s disease. Dysphagia. 2016;31(1):24–32. doi: 10.1007/s00455-015-9671-9.
  • Ilgaz F, Timur SS, Eylem CC, et al. Do thickening agents used in dysphagia diet affect drug bioavailability? Eur J Pharm Sci. 2022;174:106197. doi: 10.1016/j.ejps.2022.106197.
  • Odanaga A, Kojima H, Uno R, et al. The effect of food thickeners on the bitterness and dissolution of amlodipine besilate loaded oral disintegration tablets: assessment of potential suitability for patients with dysphagia. PP. 2022;13(10):368–378. doi: 10.4236/pp.2022.1310028.
  • Nausieda PA, Pfeiffer RF, Tagliati M, et al. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson’s disease. Clin Ther. 2005;27(1):58–63. doi: 10.1016/j.clinthera.2005.01.004.
  • Shiino K, Oshima T, Sonoda R, et al. Controlled-release fine particles prepared by melt adsorption for orally disintegrating tablets. Chem Pharm Bull. 2019;67(10):1152–1159. doi: 10.1248/cpb.c19-00554.
  • Goel H, Rai P, Rana V, et al. Orally disintegrating systems: innovations in formulation and technology. Recent Pat Drug Deliv Formul. 2008;2(3):258–274. doi: 10.2174/187221108786241660.
  • Ghourichay MP, Kiaie SH, Nokhodchi A, et al. Formulation and quality control of orally disintegrating tablets (ODTs): recent advances and perspectives. Biomed Res Int. 2021;2021:6618934–6618912. doi: 10.1155/2021/6618934.
  • Li Z, Lin X, Shen L, et al. Composite particles based on particle engineering for direct compaction. Int J Pharm. 2017;519(1-2):272–286. doi: 10.1016/j.ijpharm.2017.01.030.
  • Zhang Y, Li Z, Tang H, et al. Development and optimization of levodopa and benzylhydrazine orally disintegrating tablets by direct compression and response surface methodology. Drug Dev Ind Pharm. 2020;46(1):42–49. doi: 10.1080/03639045.2019.1698597.
  • Mennini N, Orlandini S, Furlanetto S, et al. Development and optimization by quality by design strategies of frovatriptan orally disintegrating tablets for migraine management. Curr Drug Deliv. 2018;15(3):436–445. doi: 10.2174/1567201814666170606100536.
  • Karimifard S, Alavi Moghaddam MR. Application of response surface methodology in physicochemical removal of dyes from wastewater: a critical review. Sci Total Environ. 2018;650(Pt 1):696. doi: 10.1016/j.scitotenv.2018.05.355.
  • Al-Akayleh F, Jaber N, Al-Remawi M. Designing, preparation, and evaluation of orodispersible chitosan anionic salt tablets. J Pharm Innov. 2020;17(1):129–141. doi: 10.1007/s12247-020-09497-3.
  • Morin G, Briens L. The effect of lubricants on powder flowability for pharmaceutical application. AAPS PharmSciTech. 2013;14(3):1158–1168. doi: 10.1208/s12249-013-0007-5.
  • Lakio S, Vajna B, Farkas I, et al. Challenges in detecting magnesium stearate distribution in tablets. AAPS PharmSciTech. 2013;14(1):435–444. doi: 10.1208/s12249-013-9927-3.
  • Bolhuis GK, Smallenbroek AJ, Lerk CF. Interaction of tablet disintegrants and magnesium stearate during mixing I: effect on tablet disintegration. J Pharm Sci. 1981;70(12):1328–1330. doi: 10.1002/jps.2600701210.
  • Chowhan ZT, Chi L-H. Drug-Excipient interactions resulting from powder mixing IV: role of lubricants and their effect on in vitro dissolution. J Pharm Sci. 1986;75(6):542–545. doi: 10.1002/jps.2600750604.
  • Senek M, Nyholm D, Nielsen EI. Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson’s disease patients. Eur J Clin Pharmacol. 2018;74(10):1299–1307. doi: 10.1007/s00228-018-2497-2.
  • Nakamura S, Yamaguchi S, Hiraide R, et al. Setting ideal lubricant mixing time for manufacturing tablets by evaluating powder flowability. AAPS PharmSciTech. 2017;18(7):2832–2840. doi: 10.1208/s12249-017-0765-6.
  • Wang H, Gan YC, Geng HY, et al. MyElas: an automatized tool-kit for high-throughput calculation, post-processing and visualization of elasticity and related properties of solids. Comput Phys Commun. 2022;281:108495. doi: 10.1016/j.cpc.2022.108495.
  • Scudder JM, Ellison SL, El Meddah El Idrissi L, et al. Conversions between gas-phase metallicities in MaNGA. Mon Not R Astron Soc. 2021;507(2):2468–2487. doi: 10.1093/mnras/stab2339.
  • Wilding-McBride D, Dagley LF, Spall SK, et al. Simplifying MS1 and MS2 spectra to achieve lower mass error, more dynamic range, and higher peptide identification confidence on the bruker timsTOF pro. PLOS One. 2022;17(7):e0271025. doi: 10.1371/journal.pone.0271025.
  • Ye RZ, Noll C, Richard G, et al. DeepImageTranslator: a free, user-friendly graphical interface for image translation using deep-learning and its applications in 3D CT image analysis. SLAS Technol. 2022;27(1):76–84. doi: 10.1016/j.slast.2021.10.014.
  • Committee NP. Pharmacopoeia of the People’s Republic of China. Beijing: China Pharmaceutical Press; 2020.
  • American Society for Testing Materials (ASTM). Standard test method for bulk solids characterization by Carr indices. American: ASTM; 2021. Standard No. D6393/D6393M-21.
  • Abouhussein DMN, El Nabarawi MA, Shalaby SH, et al. Sertraline-cyclodextrin complex orodispersible sublingual tablet: optimization, stability, and pharmacokinetics. J Pharm Innov. 2019;16(1):53–66. doi: 10.1007/s12247-019-09416-1.
  • Usman S, Ejaz RR, Safdar KA. Formulation development and optimization of orally disintegrating tablets of montelukast sodium by design-expert. Trop J Pharm Res. 2018;17(9):1701–1709. doi: 10.4314/tjpr.v17i9.3.
  • Monajjemzadeh F, Hassanzadeh D, Valizadeh H, et al. Compatibility studies of acyclovir and lactose in physical mixtures and commercial tablets. Eur J Pharm Biopharm. 2009;73(3):404–413. doi: 10.1016/j.ejpb.2009.06.012.
  • Dansereau RJ, Crail DJ. Compatibility of risedronate sodium tablets with food thickeners. Am J Health Syst Pharm. 2008;65(22):2133–2136. doi: 10.2146/ajhp070667.
  • Wu T, Wang G, Shi C, et al. Development and evaluation of orally disintegrating tablets containing the mosapride resin complex. Acta Pharm. 2018;68(2):159–170. doi: 10.2478/acph-2018-0017.
  • Khan A, Qayum M, Ahmad L, et al. Optimization of diluents on the basis of SeDeM-ODT expert system for formulation development of ODTs of glimepiride. Adv Powder Technol. 2022;33(2):103389. doi: 10.1016/j.apt.2021.12.008.
  • Abe H, Otsuka M. Effects of lubricant-mixing time on prolongation of dissolution time and its prediction by measuring near infrared spectra from tablets. Drug Dev Ind Pharm. 2012;38(4):412–419. doi: 10.3109/03639045.2011.608679.
  • Suresh S, Pandit V, Joshi HP. Preparation and evaluation of mouth dissolving tablets of salbutamol sulphate. Indian J Pharm Sci. 2007;69(3):467–469. doi: 10.4103/0250-474X.34568.
  • Paul S, Sun CC. Lubrication with magnesium stearate increases tablet brittleness. Powder Technol. 2017;309:126–132. doi: 10.1016/j.powtec.2016.12.012.
  • Abdelmonem R, Abdellatif MM, Al-Samadi IEI, et al. Formulation and evaluation of Baclofen-Meloxicam orally disintegrating tablets (ODTs) using Co-Processed excipients and improvement of ODTs performance using six sigma method. Drug Des Devel Ther. 2021;15:4383–4402. doi: 10.2147/DDDT.S327193.
  • El-Refai K, Teaima MH, El-Nabarawi MA. Dual-purpose vardenafil hydrochloride/dapoxetine hydrochloride orodispersible tablets: in vitro formulation/evaluation, stability study and in vivo comparative pharmacokinetic study in healthy human subjects. Drug Dev Ind Pharm. 2018;44(6):988–1000. doi: 10.1080/03639045.2018.1427761.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.